Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.
(2011) In Primary Care Diabetes 5(2). p.89-94- Abstract
AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice.
METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented.
RESULTS: During the course of the study, 1154 patients were included (age range 20-95 years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to... (More)
AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice.
METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented.
RESULTS: During the course of the study, 1154 patients were included (age range 20-95 years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total).
CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden.
(Less)
- author
- Berntorp, Kerstin LU ; Haglund, Mattias LU ; Sjövall Larsen, Sara ; Petruckevitch, Ann and Landin-Olsson, Mona LU
- author collaboration
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Aged, Aged, 80 and over, Biomarkers/blood, Biphasic Insulins, Blood Glucose/drug effects, Body Weight/drug effects, Diabetes Mellitus, Type 2/blood, Female, Glycated Hemoglobin/metabolism, Health Services Research, Humans, Hypoglycemia/chemically induced, Hypoglycemic Agents/adverse effects, Insulin/adverse effects, Insulin Aspart, Insulin, Isophane, Male, Middle Aged, Primary Health Care, Prospective Studies, Sweden/epidemiology, Time Factors, Treatment Outcome, Young Adult
- in
- Primary Care Diabetes
- volume
- 5
- issue
- 2
- pages
- 6 pages
- publisher
- Elsevier
- external identifiers
-
- wos:000304279500004
- pmid:21440523
- scopus:79958858255
- pmid:21440523
- ISSN
- 1878-0210
- DOI
- 10.1016/j.pcd.2011.02.003
- language
- English
- LU publication?
- yes
- id
- 38dbfdd3-cace-4b15-b000-55bfe380ed14 (old id 1883404)
- date added to LUP
- 2016-04-04 07:27:16
- date last changed
- 2025-04-04 14:15:00
@article{38dbfdd3-cace-4b15-b000-55bfe380ed14,
abstract = {{<p>AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice.</p><p>METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented.</p><p>RESULTS: During the course of the study, 1154 patients were included (age range 20-95 years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total).</p><p>CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden.</p>}},
author = {{Berntorp, Kerstin and Haglund, Mattias and Sjövall Larsen, Sara and Petruckevitch, Ann and Landin-Olsson, Mona}},
issn = {{1878-0210}},
keywords = {{Adult; Aged; Aged, 80 and over; Biomarkers/blood; Biphasic Insulins; Blood Glucose/drug effects; Body Weight/drug effects; Diabetes Mellitus, Type 2/blood; Female; Glycated Hemoglobin/metabolism; Health Services Research; Humans; Hypoglycemia/chemically induced; Hypoglycemic Agents/adverse effects; Insulin/adverse effects; Insulin Aspart; Insulin, Isophane; Male; Middle Aged; Primary Health Care; Prospective Studies; Sweden/epidemiology; Time Factors; Treatment Outcome; Young Adult}},
language = {{eng}},
number = {{2}},
pages = {{89--94}},
publisher = {{Elsevier}},
series = {{Primary Care Diabetes}},
title = {{Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.}},
url = {{http://dx.doi.org/10.1016/j.pcd.2011.02.003}},
doi = {{10.1016/j.pcd.2011.02.003}},
volume = {{5}},
year = {{2011}},
}